Browse
Submit Data
Databases
API
Help

Dataset Information

26 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon

ABSTRACT: RATIONALE: Beclomethasone may be an effective treatment for graft-versus-host disease. PURPOSE: Phase I/II trial to study the effectiveness of beclomethasone in treating patients who have graft-versus-host disease of the esophagus, stomach, small intestine, or colon.

DISEASE(S): Myelodysplastic Syndromes,Neoplasms, Germ Cell And Embryonal,Extramedullary Plasmacytoma,Myeloproliferative Disorders,Leukemia,Trophoblastic Neoplasms,Preleukemia,Multiple Myeloma And Plasma Cell Neoplasm,Graft Versus Host Disease,Burkitt Lymphoma,Neuroblastoma,Breast Neoplasms,Lymphoma,Breast Cancer,Testicular Germ Cell Tumor,Neoplasms,Gestational Trophoblastic Tumor,Ovarian Cancer,Plasmacytoma,Graft Vs Host Disease,Kidney Cancer,Neoplasms, Plasma Cell,Multiple Myeloma,Chronic Myeloproliferative Disorders

PROVIDER: 2005776 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Graft versus host disease treatment with mesenchymal stem cells

Project description:graft versus host disease organoids were co-cultured with mesenchymal stem cells

2024-05-22 | PXD034822 | Pride

Transcriptome analysis of acute graft-versus-host disease in children

Project description:Transcriptome analysis of acute graft-versus-host disease in children

| PRJNA706045 | ENA

Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies

Project description:This phase II trial studies how well cyclophosphamide works in preventing chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplant in patients with hematological malignancies. Giving chemotherapy and total-body irradiation before transplantation helps stop the growth of cancer cells and prevents the patient’s immune system from rejecting the donor’s stem cells. Healthy stem cells from a donor that are infused into the patient help the patient’s bone marrow make blood cells; red blood cells, white blood cells, and platelets. Sometimes, however, the transplanted donor cells can cause an immune response against the body’s normal cells, which is called graft-versus-host disease (GVHD). Giving cyclophosphamide after transplant may prevent this from happening or may make chronic GVHD less severe.

| 2112331 | ecrin-mdr-crc

CIDR: Genetics of Graft-vs-Host Disease

Project description:CIDR: Genetics of Graft-vs-Host Disease

| PRJNA671477 | ENA

CIDR: Genetics of Graft-vs-Host Disease

Project description:CIDR: Genetics of Graft-vs-Host Disease

| PRJNA671478 | ENA

FRCs promote Treg function in acute graft-versus-host disease (aGvHD)

Project description:FRCs promote Treg function in acute graft-versus-host disease (aGvHD)

| PRJNA706037 | ENA

Granzyme A-producing CD4+ T cells in graft-versus-host disease

Project description:Granzyme A-producing CD4+ T cells in graft-versus-host disease

| PRJNA646973 | ENA

Anti-CX3CL1 (fractalkine) monoclonal antibody attenuates lung and skin fibrosis in sclerodermatous graft-versus-host disease mouse model

Project description:To assess the preclinical utility and functional mechanism of intraperitoneal anti-CX3CL1 mAb therapy in the skin and lung fibrosis, sclerodermatous chronic graft-versus-host disease (Scl-cGVHD) model mice were analyzed by RNA-sequencing assays.

2024-05-03 | GSE227285 | GEO

Epigenetic changes from ATAC-seq of intestine stem cells from mice with graft-versus-host disease

Project description:Intestinal stem cells (ISC) encounter inflammatory insults in immune mediated gastro-intestinal (GI) diseases. It remains unknown whether, and how, they adapt, and if the adaptation leaves scars on the ISCs that affects their subsequent regeneration capacity. We investigated the consequences of inflammation on Lgr5+ISCs in well-defined clinically relevant models of gastro-intestinal acute graft-versus-host disease (GI GVHD). Utilizing single cell transcriptomics, organoid, metabolic, epigenomic and in vivo models we found that Lgr5+ISCs undergo metabolic changes that lead to accumulation of succinate, which reprograms its epigenome. We performed transposase-accessible chromatin sequencing (ATAC-seq) in sorted Lgr5+ISCs harvested from the BALB/c→B6-GFP-Lgr5 model of GVHD.

2024-09-11 | GSE223814 | GEO

CD8+ T cell response in the Act-mOVA/OT-I model of acute graft versus host disease

Project description:Lethally irradiated C57Bl/6 Act-mOVA mice receiving allogeneic hematopoietic stem cell transplantation (aHSCT) from C57Bl/6 OT-I animals develop acute graft versus host disease (aGvHD) in a CD8+ T cell-dependent, reproducible manner, and succumb to the disease within 4-7 days. Tracking of UBC-GFP/OT-I graft CD8+ T cells discloses heavy infiltration of the GI tract, liver and lungs at the onset of the disease, and hallmark histologic features of acute gastrointestinal and hepatic GvHD, and aGVHD-associated lymphocytic bronchitis. This dataset describes gene expression patterns of CD45.1/OT-1 CD8+ T cells retrieved from the graft before (aHSCT + Day 0), and from various target organs of the host after (aHSCT + Day 4) grafting them into Act-mOVA recipients.

2019-03-01 | GSE79083 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data